Novavax Inc (NVAX.O)

NVAX.O on Nasdaq

3 Jun 2015
Change (% chg)

$0.02 (+0.22%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for NVAX.O


Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company focusing on developing recombinant vaccines. The Company’s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company's vaccine candidates are genetically engineered three-dimensional nanostructure... (more)


Beta: 1.17
Market Cap(Mil.): $2,382.79
Shares Outstanding(Mil.): 268.03
Dividend: --
Yield (%): --


  NVAX.O Industry Sector
P/E (TTM): -- 312.37 38.84
EPS (TTM): -0.40 -- --
ROI: -30.41 -5.21 16.53
ROE: -31.66 -6.13 17.62
Search Stocks

Novavax starts Ebola vaccine trial in humans

- Novavax Inc has begun early-stage human trials of an Ebola vaccine that it hopes can win the race to become the most effective shot for the deadly virus.

12 Feb 2015

UPDATE 1-Novavax starts Ebola vaccine trial in humans

* Co says can manufacture millions of doses a month (Adds CEO comment, detail)

12 Feb 2015

Novavax starts Ebola vaccine trial in humans

Feb 12 - Novavax Inc has begun early-stage testing of its Ebola vaccine in humans, the company said, less than five months after entering the race to develop a shot for the deadly virus.

12 Feb 2015


  Price Chg
Novartis AG (NOVN.VX) CHF97.00 +0.70
Merck & Co., Inc. (MRK.N) $60.39 +0.15
Sanofi SA (SASY.PA) €91.12 +1.48
GlaxoSmithKline plc (GSK.L) 1,437.50p -3.50
AstraZeneca plc (AZN.L) 4,390.00p +33.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: ValuEngine, Inc.
Provider: Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks